Back HIV Populations Injection Drug Users

Injection Drug Users

HIV Risk Behavior Remains Common Among People Who Inject Drugs in U.S.

An analysis from the CDC's National HIV Behavioral Surveillance system found that 11% of injection drug users in 20 U.S. cities were HIV-positive in 2012, according to a report in the March 20 Morbidity and Mortality Weekly Report. One-third of the interviewees reported sharing used injection equipment, putting them at risk for acquiring HIV and hepatitis B and C, while a majority reported sex without condoms.

alt

Read more:

Hepatitis C Infections Fall after Harm Reduction Scale-up in Scotland

Hepatitis C virus (HCV) incidence among people who inject drugs declined rapidly after national scale-up of harm reduction interventions such as syringe exchange in Scotland, according to a report published in the August 11 edition of PLoS ONE. Changes in HCV prevalence, however, are lagging behind.

alt

Read more:

Studies Reveal HIV and HCV Epidemics Among Injection Drug Users in the Middle East and North Africa

At least one-third of countries in the Middle East and North Africa that historically have had low rates of HIV infection now have emerging epidemics largely attributable to injection drug use, according to a systematic review published in the June 17 edition of the open access journal PLoS Medicine. Rates of hepatitis C virus (HCV) infection also appear to be high and rising.

alt

Read more:

AIDS 2014: Harm Reduction Funding Is Meeting Only 7% of Global Need

International donors are investing only 7% of what is needed to provide adequate harm reduction coverage for people who inject drugs, according to findings from a report presented this week at the 20th International AIDS Conference in Melbourne. A global commitment to re-balance spending on drug control and harm reduction is essential in order to achieve control of HIV and viral hepatitis among drug injectors, several speakers told the conference.

alt

Read more:

CROI 2014: Monkey Studies Confirm Validity of Injectable PrEP

Two studies in monkeys of an injectable formulation of the third-generation integrase inhibitor drug GSK1265744 (or GSK744LA, where LA stands for "long-acting") have strengthened the evidence that it may work as pre-exposure prophylaxis (PrEP) in humans, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. A Phase 2 study in humans will be starting soon.

alt

Read more: